WallStSmart

Abbott Laboratories (ABT)vsVicarious Surgical Inc. (RBOT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ABT leads profitability with a 14.7% profit margin vs 0.0%. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

RBOT

Avoid

29

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for RBOT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

RBOT1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RBOT4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.84M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : RBOT

The strongest argument for RBOT centers on Price/Book.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : RBOT

The primary concerns for RBOT are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

RBOT carries more volatility with a beta of 1.55 — expect wider price swings.

ABT is growing revenue faster at 4.4% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (51/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Vicarious Surgical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Vicarious Surgical Inc. (RBOT) is an innovative medical technology company focused on transforming surgical practices through its state-of-the-art robotic surgical systems that enhance precision and improve patient outcomes. By combining advanced robotics with artificial intelligence, Vicarious Surgical is pioneering a new era of minimally invasive surgery, offering surgeons superior dexterity, visualization, and control. The company's proprietary platform not only enhances surgical efficiency but also strives to minimize patient recovery times, thereby responding to the increasing demand for robotic-assisted procedures. As a leader in the rapidly growing surgical robotics market, Vicarious Surgical is dedicated to advancing patient care and addressing the evolving challenges within the healthcare sector.

Want to dig deeper into these stocks?